NEW YORK (GenomeWeb News) – BGI-Shenzhen and Complete Genomics said today that their proposed merger has cleared US antitrust review.
The companies said that they have received early termination of the Hart-Scott-Rodino waiting period from the Federal Trade Commission regarding BGI's $118 million bid for Complete.
The news comes one week after the Committee on Foreign Investment in the United States cleared the proposed acquisition.
BGI also said today that it has extended its tender offer for Complete's shares to midnight EST on Jan 11. The offer had originally been scheduled to expire on Dec. 31, 2012, and was later extended to expire at midnight today.